Insomnia Treatment Market: How Top Leading Companies Can Make This Smart Strategy Work – Cole of Duty

In 2025, the market size of the Insomnia Treatment Market is expected to touch million US$ xx million. The revenue registered in 2018 was US$ xx million, thus depicting a growth at a CAGR of xx% from 2018. While in China, the market size was valued at US$ xx million in the forecast base year, further projected to increase up to US$ xx million till the end of 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Insomnia Treatment .

This report studies the global market size of Insomnia Treatment , especially focusing on the key regions such as United States, European Union, China, and other geographical extents (Japan, Korea, India, and Southeast Asia).

Request Sample Report @https://www.mrrse.com/sample/16585?source=atm

This study presents the Insomnia Treatment market production, revenue, market share, and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. The historical data breakdown for Insomnia Treatment for 2014-2018 is provided in the report along with company projection for 2018 to 2025.

For top companies in United States, European Union, and China, this report investigates and analyzes the production, value, price, market share, and growth rate for the manufacturers, key data from 2018 to 2025.

segmented as follows:

This report encompasses the global insomnia treatment market performance in terms of revenue contribution from various segments and also gives an overview of the insomnia sleep disorder, sleep aids and other definitions. Macro-economic factors influencing growth of the insomnia treatment market along with detailing opportunity analysis of market are also outlined.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments, growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global insomnia treatment market.

The global insomnia treatment market is segmented based on drug type, distribution channel and region. On the basis of drug type market has been segmented as OTC drugs and prescription drugs. On the basis of distribution channel market has been segmented as hospital pharmacies, retail pharmacies, e-commerce and drug stores & hypermarkets. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractiveness index. The report also gives a comprehensive overview of the regional market dynamics along with key growth driver, restraints, and trends pertaining to each region, which can be useful to understand the investment and collaboration opportunities in major countries. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific (APAC), and MEA.

Competitive Landscape

This section is included in the report to provide insights on the key players in the global insomnia treatment market and is primarily designed to furnish a detailed comparative assessment of service offerings and strategies of key providers specific to market segments. Detailed profiles of players in insomnia treatment market are also provided in the report which highlights company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

Research Methodology

To arrive at the market size, Persistence Market Research considered parent market statistics i.e. stem cell market in each region and share of insomnia treatment market. A bottom-up approach was used to validate the total market size obtained. The report provides total revenue of insomnia treatment market over the forecast period 20182026. While forecasting the market size, several factors such as approvals for insomnia treatment drugs, R&D investment by major players, and consumption of drugs by different end users have been considered. However, to quantifying the market across the aforementioned segments and regions, market expectations and opportunities have been considered. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global insomnia treatment market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16585?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 describes Insomnia Treatment product/service scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2 profiles the top manufacturers of Insomnia Treatment market, with price, sales, revenue and global market share of Insomnia Treatment from 2014 2018.

Chapter 3 analyses the Insomnia Treatment competitive situation, sales, revenue. The global Insomnia Treatment market shares of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4 showcases the Insomnia Treatment breakdown data at the regional level, to discuss the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8, and 9 emphasize the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2014 to 2018.

Chapter 10 and 11 explain the segments by sales under type and application, with market shares and growth rate under each category, from 2014 to 2018.

Chapter 12 depicts Insomnia Treatment market forecasts by region, type, and application, with sales and revenue projections, from 2018 to 2025.

Chapter 13 and 14 describe Insomnia Treatment sales channel, distributors, customers, research findings and conclusion, appendix, and other data sources.

Buy This Report @ https://www.mrrse.com/checkout/16585?source=atm

More here:
Insomnia Treatment Market: How Top Leading Companies Can Make This Smart Strategy Work - Cole of Duty

COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 – Daily Research…

"Global Thoracic Catheters Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Thoracic Catheters market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Thoracic Catheters Market. The report begins with the introduction on Thoracic Catheters Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Thoracic Catheters manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The Thoracic Catheters production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Thoracic Catheters Industry are: Medtronic Teleflex Smiths Medical Atrium Medela Redax Atmos Sorin Argon Cook Medical PAHSCO Diversatek

Top Product Types Evaluated are: Catheter Analog Digital

Top Applications studied are: Pneumothorax Pleural Effusion Others

To derive the vital Thoracic Catheters Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Thoracic Catheters Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Thoracic Catheters Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Thoracic Catheters Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Thoracic Catheters Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Thoracic Catheters Market. North America is expected to reach a higher market share followed by the European region. Demand for Thoracic Catheters products and its relevant applications across different market segments is growing rapidly.

Thoracic Catheters Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Thoracic Catheters Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Thoracic Catheters industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Thoracic Catheters Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

Read the original:
COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 - Daily Research...

Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19 – GlobeNewswire

July 13, 2020 09:00 ET | Source: Avalon GloboCare Corp.

FREEHOLD, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its four scientific research and clinical development programs in cell therapy and COVID-19 related initiatives, including AVA-001 and AVA-011 (FLASH-CAR), that leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy for immuno-oncology, as well as AVA-Trapfor mitigating COVID-19 cytokine storm, and S-layer based COVID-19 vaccine development.

AVA-001

Avalon has successfully completed a Phase I first-in-human clinical study of its leading CAR T-cell therapy candidate, AVA-001 (National Institute of Health clinical trial registration number: NCT03952923). AVA-001 is a third generation CAR T-cell therapy which involves the 4-1BB (or CD28) co-stimulation signaling pathway. Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after receiving one dose of AVA-001 CAR T-cell therapy. The treatment with AVA-001 was generally well tolerated with minimal adverse side effects: no neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent. Accessory laboratory testing that accompanied this pilot clinical study has demonstrated evidence of enhancement in CAR T cell persistence and protection against CAR T cell exhaustion. This paradigm of bridging CAR T-cell therapy to bone marrow transplant creates a new therapeutic horizon with curative potential for patients with relapsed/refractory B-ALL and other hematologic cancers. Avalon is in the process of extending AVA-001 CAR T-cell therapy to the next phases of clinical development.

AVA-011 (FLASH-CAR)

Avalons FLASH-CARuses next generation CAR technology to modify patients T-cells and natural killer (NK) cells using a ribonucleic acid (RNA)-based platform rather than a viral vector.Avalons RNA-based CAR technology is designed to rapidly create personalized CAR therapies in 1 to 2 days compared to the 10- to 14-day bio-manufacturing time necessary to generate currently available CAR-T cellular immunotherapy. Avalons FLASH-CARtechnology is also designed to reprogram the immune cells to hone in on multiple crucial cancer cell targets, called tumor antigens, to potentially achieve superior therapeutic effect. Avoiding the use of viral vectors and complicated bio-processing procedures significantly reduces manufacturing costs, resulting in a more affordable and potentially breakthrough therapy for cancer patients. The FLASH-CARtechnology can also be used to generate off-the-shelf, universal cell therapy that has the potential to reach even more patients. Avalons first FLASH-CARplatform candidate, AVA-011, targets both CD19 and CD22 tumor antigens on cancer cells. Pre-clinical research on AVA-011, including tumor cytotoxicity studies, has been successfully completed and Avalon is immediately entering the process development stage to generate clinical-grade CAR-T and CAR-NK cells for use in human clinical trials. Avalon expects to begin a first-in-human clinical trial with AVA-011 for the treatment of relapsed/refractory B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma in the first quarter of 2021. The goal is to apply AVA-011 as a bridge to bone marrow stem cell transplant therapy with curative potential for patients with these blood cancers.

Avalon GloboCare, has established the Avalon Combat COVID-19 Taskforce (ACCT) to expand and accelerate scientific/clinical development on multiple fronts to help combat the COVID-19 global pandemic through a strategic combination of therapeutic and vaccine approaches as follows:

AVA-Trap

Avalon has engaged with Massachusetts Institute of Technology (MIT) to co-develop a QTY therapeutic platform against the cytokine storm which causes lung damage and other organ failure associated with COVID-19. Cytokines are small protein molecules in the body required to regulate and maintain proper physiological functions. In some life-threatening diseases, however, cytokines are released in vast excess (also known as cytokine storm) leading to devastating damage to vital tissues and organs. A prime example is the widely recognized SARS-CoV-2 (COVID-19)-induced cytokine storm, which can lead to acute respiratory distress syndrome, lung fibrosis, multi-organ failure and death. The pre-clinical result has been published in the journal QRB Discovery (Cambridge University Press). Three USPTO provisional patents have been filed based on the unique QTY code protein design platform that uses six water-soluble variant cytokine receptors which have been successfully designed and tested to show binding affinity to the respective cytokines. Avalons AVA-Trap therapeutic program is currently entering animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms.

Intranasal and Oral COVID-19 Candidate Vaccine

Formed a strategic partnership program between Avalon GloboCare and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. The goal is to co-develop an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2 (COVID-19). This partnership is led by BOKUs Professor Uwe B. Sleytr, an eminent member of the Austrian Academy of Sciences, who is a pioneer of applied surface layer (S-layer) nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. This vaccine strategy has the dual advantages of ease of manufacturing and delivery. The candidate vaccine is derived from a fusion of an S-layer viral particle mimic with the SARS-CoV-2 spike protein and could be delivered non-invasively via the nasal or oral passageways, rather than a needle-based injection into the muscle or under the skin. The S-layer protein-based vaccine is expected to both decrease the severity of a SARS-CoV-2 infectionpreventing the more severe respiratory inflammation and organ damage seen in many COVID-19 patientsand build immunity against the virus. Substantial progress has been made by developing the proprietary techniques necessary to synthesize conjugate vaccines consisting of an S-layer artificial viral envelope linked to a viral antigen, eliciting immune-protective antibody responses. Avalon plans to complete the proof-of-concept pre-clinical studies in 2020, followed by first-in-human clinical study of this candidate vaccine during 2021. In addition, Avalon plans to utilize S-layer technology to accelerate additional vaccine programs for other respiratory infections including different strains of the flu (influenza A/B), respiratory syncytial virus (RSV), and other viruses. Avalon is also actively exploring other practical uses of S-layer technology including targeted drug delivery, diagnostic devices, and therapeutic applications.

We are excited and encouraged by the progress in advancing our scientific and clinical programs targeting immune-oncology and COVID-19, stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. As an active, clinical-stage company with innovative technology, productive partnerships and exceptional talent, we are committed to delivering effective execution and leadership to combat cancer and COVID-19, added Dr. Jin.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX), and regenerative therapeutics. For more information about Avalon GloboCare, please visit http://www.avalon-globocare.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information: Avalon GloboCare Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728 PR@Avalon-GloboCare.com

Investor Relations: Crescendo Communications, LLC Tel: (212) 671-1020 Ext. 304 avco@crescendo-ir.com

Link:
Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19 - GlobeNewswire

COVID-19 Impact On Global Adult Toys Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 – Cole of Duty

"Global Stem Cell Therapy Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Stem Cell Therapy market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Stem Cell Therapy Market. The report begins with the introduction on Stem Cell Therapy Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Stem Cell Therapy manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The Stem Cell Therapy production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Stem Cell Therapy Industry are: Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCRPharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

Top Product Types Evaluated are: Autologous Allogeneic

Top Applications studied are: Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

To derive the vital Stem Cell Therapy Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Stem Cell Therapy Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Stem Cell Therapy Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Stem Cell Therapy Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Stem Cell Therapy Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Stem Cell Therapy Market. North America is expected to reach a higher market share followed by the European region. Demand for Stem Cell Therapy products and its relevant applications across different market segments is growing rapidly.

Stem Cell Therapy Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Stem Cell Therapy Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Stem Cell Therapy industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Stem Cell Therapy Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

More here:
COVID-19 Impact On Global Adult Toys Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 - Cole of Duty

Impact of COVID-19 on Autoimmune Treatment Market 20202025 Global Size, Growth, Trends, Applications, Demand Analysis, Key Players and 2025 Forecast…

The launch of novel biomarkers is expected to enhance the autoimmune diagnosis, which is likely to encourage the growth of the global Autoimmune Treatment market in the forecast period. In addition, the technological advancements in laboratory automation platforms and the rising number of product approval and launches are anticipated to accelerate the growth of the market in the coming years.

For Sample Copy of this Report Visit @https://www.orianresearch.com/request-sample/722397

Impact of COVID-19 Outbreak on this Market:

The rise of COVID-19 has brought the world to a halt. We comprehend that this health crisis has brought an unprecedented impact on organizations across industries. However, this too shall pass. Rising helps from governments and several companies can help in the battle against this highly contagious disease. There are few industries that are struggling and some are thriving. Almost every organization is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business to continue and develop COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.

Based on technology, the Autoimmune Treatment market is segmented as bridge therapy, phototherapy, topical therapy, fecal bacteriotherapy, recombinant technology, diseases-modifying antirheumatic drugs, helminthic therapy, and hematopoietic stem cell transplantation. Rheumatoid arthritis leads the global Autoimmune Treatment market, due to high prevalence of rheumatoid arthritis worldwide

Regionally, North America leads the global Autoimmune Treatment market, due to aging population, high incidences of autoimmune diseases, increased healthcare expenditure, and excessive R&D investment for the development of drugs for autoimmune diseases

Global Autoimmune Treatment market is dominated by Abott, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi, GlaxoSmithKline PLC, Biogen, Boehringer Ingelheim GmbH, AstraZeneca PLC, and Astellas Pharma Inc.

Global Autoimmune Treatment Industry is spread across 121 pages, profiling 16 companies and supported with tables and figures.

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/722397.

Key Benefits of the Report:

* Global, Regional, Country, Insight Type, and Application Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTEL, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Insight Type & Application, and competitive landscape with qualitative and quantitative information and facts

Target Audience:

* Autoimmune Treatment providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies

Order a copy of Global Autoimmune Treatment Market Report 2020 @https://www.orianresearch.com/checkout/722397.

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity production, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Equipment Manufacturer,

* Application Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute

TABLE OF CONTENT

1 Executive Summary

2 Methodology And Market Scope

3 Autoimmune Treatment Market Industry Outlook

4 Autoimmune Treatment Market Application Outlook

5 Autoimmune Treatment Market Technology Outlook

6 Autoimmune Treatment Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us Orian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See the original post:
Impact of COVID-19 on Autoimmune Treatment Market 20202025 Global Size, Growth, Trends, Applications, Demand Analysis, Key Players and 2025 Forecast...

SMD – Scientists discover protective Alzheimer’s gene and develop rapid drug-testing platform – QMUL

10 July 2020

The main challenge in testing Alzheimers drugs in clinical trials is that participants need to have symptoms. But once people have symptoms, it is usually too late for treatments to have a significant effect, as many brain cells have already died.

The only current way to test potential preventative treatments is by identifying participants who are at higher risk of developing Alzheimers and seeing if treatments prevent the onset of their disease. This includes people with Down's syndrome (DS) who have around a 70 per cent chance of developing Alzheimers during their lifetime. This is because the extra chromosome 21 they carry includes the gene for amyloid precursor protein which causes early Alzheimers when overdosed or mutated.

In the study, published in the Nature group journal Molecular Psychiatry, the researchers collected hair cells from people with DS and reprogrammed them to become stem cells, which were then directed to turn into brain cells in a dish.

In these brain-like cells, the researchers saw Alzheimers-like pathology develop rapidly, including the hallmark trio of signs of Alzheimers progression - amyloid plaque-like lesions, progressive neuronal death and abnormal accumulations of a protein called tau inside neurons.

Lead researcher Professor Dean Nietifrom Queen Mary's Blizard Institute commented: This work represents a remarkable achievement, as this is the first cell-based system that has the full trio of Alzheimers-pathologies, without any artificial gene overexpression. This system opens up the prospect for screening for new drugs aimed at delaying or even preventing Alzheimers before neuronal death starts.

The researchers showed that the system could be used as an early preventative-drug testing platform. They took two different drugs which are known to inhibit -amyloid production, tested them on these brain cells, and in six weeks showed that they prevented the onset of Alzheimers-pathology.

Although these two particular drugs have failed clinical trials for other reasons and therefore arent suitable treatments for Alzheimers, the team showed the proof-of-principle that the system can be used on any drug compound, and within six weeks show whether or not it has potential for further investigation.

The team also found proof of the existence of a naturally-functioning Alzheimers suppressor gene (BACE2 gene). Acting in a similar way to tumour suppressor genes in cancer, the increased activity of this gene contributes to the prevention/slowing down of Alzheimers in human brain tissue, and could in the future be used as a biomarker to determine peoples risk of developing the disease, or as a new therapeutic approach by boosting its action.

Professor Dean Nietiexplained: Although its still early days, the system raises a theoretical possibility for further development as a tool to predict who might develop Alzheimers. The same stem cell process could be used on anyones hair follicles, the resulting brain cells of which may or may not then develop Alzheimers-pathology in the dish. The idea would be to catch the people at higher risk of early disease in a cell-based system, before it starts in a persons brain, and allow for the possibilities of individualised preventive interventions. We are still a long way from reaching this goal.

Co-author Professor John Hardy from UCL added: I think we have the potential now to develop a new, human model of the disease which would be a great step forward.

The discoveries in this study were dependent on contributions from people with DS who kindly accepted to participate in this study, the results of which could be beneficial for people with and without DS in preventing Alzheimers. The Downs Syndrome Association (UK) provided essential support and help with recruitment of the participants in the study.

Carol Boys, Chief Executive of the Downs Syndrome Association, said: These are exciting results from an extremely eminent group of researchers and another small step towards a possible intervention and treatment for Alzheimers Disease. The Downs Syndrome Association is delighted to have been able to support this brilliant work.

The main funders of the project were Wellcome (UK) and National Medical Research Council (Singapore), and involved major contributions from the Nanyang Technological University Singapore, UCL (Prof. John Hardy and Prof. Henrik Zetterberg) and Sahlgrenska Academy of the University of Gothenburg, Sweden (Prof. Henrik Zetterberg), as well as a number of international partners, including The Croatian Institute for Brain Research at the University of Zagreb Medical School.

Continue reading here:
SMD - Scientists discover protective Alzheimer's gene and develop rapid drug-testing platform - QMUL